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Abstract
Purpose—Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes (TIL) has 
shown an overall clinical response rate 40–50% in metastatic melanoma patients. BTLA (B-and-T 
lymphocyte attenuator) expression on transferred CD8+ TIL was associated with better clinical 
outcome. The suppressive function of the ITIM and ITSM motifs of BTLA is well described. 
Here, we sought to determine the functional characteristics of the CD8+BTLA+TIL subset and 
define the contribution of the Grb2 motif of BTLA in T cell co-stimulation.
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Experimental Design—We determined the functional role and downstream signal of BTLA in 
both human CD8+ TIL and mouse CD8+ T cells. Functional assays were used including single 
cell analysis, Reverse Phase Protein Array (RPPA), antigen-specific vaccination models with 
adoptively transferred TCR-transgenic T cells as well as Patient-Derived Xenograft (PDX) model 
using Immunodeficient NOD-scid IL2Rgammanull (NSG) tumor-bearing mice treated with 
autologous TIL.
Results—CD8+BTLA− TIL could not control tumor growth in vivo as well as their BTLA+ 
counterpart and antigen-specific CD8+BTLA− T cells had impaired recall response to a vaccine. 
However CD8+BTLA+ TIL displayed improved survival following the killing of a tumor target 
and heightened “serial killing” capacity. Using mutants of BTLA signaling motifs we uncovered a 
costimulatory function mediated by Grb2 through enhancing the secretion of IL-2 and the 
activation of Src after TCR stimulation.
Conclusions—Our data portrays BTLA as a molecule with the singular ability to provide both 
co-stimulatory and co-inhibitory signals to activated CD8+ T cells, resulting in extended survival, 
improved tumor control and the development of a functional recall response.
Keywords
Melanoma; tumor-infiltrating lymphocytes; B and T lymphocyte attenuator; T cell survival; tumor 
control
Introduction
Adoptive T cell therapy (ACT) using the body’s own expanded tumor-infiltrating 
lymphocytes (TIL) with prior lymphodepletion and followed by high dose IL-2 
administration has demonstrated an overall response rate of 38–51% in multiple clinical 
trials for stage IIIC/IV metastatic melanoma (1–4). A comprehensive immunophenotyping 
of TIL infusion products has revealed an unexpected finding that a population of CD8+TIL 
expressing a molecule known to attenuate T cell response, the B and T lymphocyte 
attenuator (BTLA), was strongly associated with a positive clinical response (4).
BTLA is an inhibitory molecule expressed by T cells, B cells, dendritic cells, and NK cells 
(5). Herpes virus entry mediator (HVEM), a tumor necrosis factor receptor superfamily 
member 14 (TNFRSF14), is the known ligand for BTLA (6). The cytoplasmic domain of 
BTLA consists of three motifs; an immunoreceptor tyrosine-based inhibition motif (ITIM), 
an immunoreceptor tyrosine-based switch motif (ITSM), and a growth factor receptor-bound 
protein 2 motif (Grb2). Ligation of BTLA by HVEM has been shown to recruit Src 
homology 2 (SH2) domain-containing phosphatase 1 and 2 (SHP-1 and SHP-2) to the ITIM 
and ITSM motifs, resulting in suppression of T cell receptor (TCR) activation (5,7). Indeed, 
ITIM and ITSM motifs were required for the full function of BTLA to inhibit T cell 
proliferation and cytokine production including IFN-γ, IL-2, and IL-10 (8,9). A recent 
report indicated that PD-1 ligation, which also contains ITIM and ITSM motifs, selectively 
inhibits both the Akt and Ras-MEK-ERK pathways (10). So far, it remains inconclusive 
whether BTLA utilizes mechanism similar to PD-1 as ITIM and ITSM motifs are commonly 
shared between these two receptors.
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Unlike PD-1, BTLA also harbors a Grb2 motif. Although the function of the Grb2 motif 
remains unclear, some evidence suggests that it may actually transmit a positive signal. In 
fact, an in vitro binding assay demonstrated the potential interaction of the Grb2 binding 
motif with the Grb2 adaptor protein and the p85 subunit of phosphatidylinositol 3-kinase 
(p85 PI3K) (7,11). Interestingly, a gene expression analysis of mouse CD4+T cells following 
activation by anti-CD3 and anti-BTLA demonstrated a highly overlapping transcription 
profile with that produced by anti-CD3 in combination with positive co-stimulators (CD28, 
ICOS, and CD80), but not with inhibitory molecules (PD-1 and CTLA-4) (12).
Emerging evidence also demonstrates that BTLA serves as a T cell differentiation marker in 
human T cells as BTLA expression is highly enriched in naïve T cells and central memory T 
cells (Tcm) and down-regulated upon T cell differentiation (13). Our recent work 
demonstrated that CD8+BTLA+TIL exhibited the molecular signature of less-differentiated 
T cells as compared to their CD8+BTLA− counterpart and had increased persistence 
following adoptive transfer in treated patients (14). Several studies in both immunodeficient 
murine and non-human primate models also demonstrated that central memory derived 
effector CD8+ T cells established a pool of in vivo persistent memory T cells (15–18). In 
addition, adoptive transfer of memory T cell with stem cell properties (TSCM) was shown to 
confer in vivo persistence and better tumor control due to enhanced survival and anti-tumor 
properties (15).
Thus far, it remains understudied whether the intrinsic properties of less-differentiated TIL 
highly enriched in BTLA expressing cells and/or BTLA signaling itself contribute to the 
favorable clinical outcome of TIL treated patients. In this study, we have uncovered a 
survival advantages of the BTLA+ subset that allows for serial killing of target tumor cells, 
which may explain our previous correlation between this subset and response to TIL ACT. 
In addition, our results unveiled a role for the BTLA-associated Grb2-binding motif in T cell 
proliferation and IL-2 production following TCR engagement that was independent of the 
inhibitory function of ITIM/ITSM motifs. The use of a pmel BTLA knockout system 
demonstrates a weaker priming of T cells in response to the cognate antigen and the absence 
of a recall response. Overall, this study has uncovered a previously unappreciated role of the 
Grb2 motif of BTLA in providing positive co-stimulatory signal to T cells and the ability of 
CD8+BTLA+TIL to function as serial killers.
Materials and Methods
Cell lines
Platinum-E retroviral packaging cell line, MEL 526 tumor line, and primary melanoma 
tumor cell line #2549, as well as B16F10, and B16OVA were maintained in Roswell Park 
Memorial Institute (RPMI) supplemented with 10% fetal bovine serum (FBS) (Gemini bio 
product), 10 mM HEPES (Gibco™), 10 mM Penicillin-streptomycin (Gibco™), and 10 mM 
Glutamine (Gibco™), selenium-transferrin-insulin (Gibco™), and 0.05 mM Beta-
mercaptoethanol (Gibco™) as previously described (2, 34). Platinum-E retro packing cell 
line was purchased from Cellbiolabs. MEL 526 tumor line was obtained from Dr Steven A. 
Rosenberg at the National Cancer Institute. Autologous primary melanoma tumor cell line 
#2549 was generated at M.D. Anderson Cancer Center from a tumor sample of a patient 
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enrolled on an ongoing adoptive T cell therapy study. The cell line #2549 was last 
authenticated on 03/24/2015 by STR DNA fingerprinting using the Promega 16 High 
Sensitivity STR Kit (Catalog #DC2100). The STR profiles were compared to online search 
databases (DSMZ/ATCC/JCRB/RIKEN) of 2455 known profiles; along with the MD 
Anderson Characterized Cell Line Core (CCLC) database of 2556 know profiles. The STR 
profiles matched known DNA fingerprint of patient’s PBMCs. No authentication was 
performed in all other cell lines.
Patient tumor sample acquisition
Tumor samples were obtained from patients with Stage IIIc and Stage IV melanoma 
undergoing surgery at The University of Texas MD Anderson Cancer Center according to an 
Institutional Review Board-approved protocol and with patient consent (IRB# 2004-0069, 
LAB06-0755, NCT00338377). This study was carried out in compliance with the protocol 
and Good Clinical Practice concerning medical research in humans, as described in the 
Declaration of Helsinki.
Generation of TIL
Fragments from melanoma tumors were cut into 1 to 2 mm3. Each fragment was placed into 
a single wells in 24-well-culture plates (Falcon) and maintained with RPMI supplemented 
with 10% heat inactivated Human AB serum (Gemini bio product), IL-2 6000 IU/ml 
(Proleukin, Novartis), 10 mM HEPES, 10 mM Penicillin-streptomycin (Gibco™), and 10 
mM Glutamine (Gibco™) as previously described (19).
Retroviral constructs of BTLA wild-type and mutants
Murine BTLA was amplified from fully sequenced murine BTLA from Mammalian Gene 
Collection Clones (MGC, Open biosystem) by PCR with primers mBTLA-F and R 
(Supplementary Table S1). The PCR products were cloned into pRVKM retroviral vectors. 
To generate BTLA mutants, we substituted tyrosine for phenyl alanine in either Grb2 motifs 
or ITIM and ITSM motifs of BTLA cytoplasmic tails (Supplementary Table S2). These 
included murine ΔGrb2 mutants (Y245F), and murine Δ ITIM and ITSM mutants (Y274F 
and Y299F). Sequences of all constructs were validated by DNA sequencing.
Retroviral transduction of mouse BTLA-KO-T cells
pRVKM retroviral vectors and pEco plasmids were co-transfected into Plate-E cells using 
using PolyJet (Signagen Laboratories). The supernatants were harvested 60 h later and 
concentrated using Vivaspin-20 (Vivaproducts). Splenocytes from OT-1 BTLA KO mice 
were cultured with RPMI1640 with 10% FBS and hIL-2 at 300 IU/ml, and activated with 
anti-mouse CD3 at concentration of 0.3 ug/ml (Clone 145-2C11, eBioscience) for 24 h. The 
cells were then infected with a concentrated retrovirus and further expanded in RPMI1640 
with 10% FBS and hIL-2 for 3 days. The cells were sorted based on the expression of GFP 
using a FACSAria (BD Bioscience) and propagated with hIL-2 at 300 IU/ml for 5 days.
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Reverse phase protein array (RPPA)
Murine OT-1 BTLA KO cells overexpressing BTLA WT or mutants constructs were re-
stimulated with either 10 ng/ml anti-mouse CD3 (Clone 145-2C11, BD Pharmingen™) 
alone or with recombinant mouse HVEM Fc (R&D systems) plate-bound for 8 h prior to 
harvest with the cell lysis buffer (kindly provided by RPPA core facility at The University of 
Texas M.D. Anderson Cancer Center). The cell lysates were centrifuged at 14,000 rpm for 
10 minutes at 4°C. The protein supernatant was quantified using protein assay kit (Thermo 
scientific). RPPA was processed and normalized as previously described (20). Differential 
fold expression of protein was analyzed using Linear models and empirical Bayes 
methods(21). Volcano plots were generated using R system. For human TIL, four TIL lines 
were stained with anti-CD8 (clone RPA-T8, BD Pharmingen™), anti-BTLA (clone J168, 
BD Pharmingen™), and Sytox blue (Molecular Probe™) under aseptic condition. The cells 
were sorted based on expression of CD8+BTLA+ using FACSAria (BD Biosciences). On the 
next day, sorted TIL were re-stimulated with anti-human CD3 (clone OKT-3, eBioscience) 
with or without recombinant human HVEM-Fc (R&D systems) plate-bound for 8 h prior to 
harvest with the cell lysis buffer. The protein samples were processed, normalized, and 
analyzed as similar to the mouse experiment described above.
Intracellular cytokine staining
OT-1 BTLA KO T cells overexpressing BTLA WT or mutants were re-activated with either 
dendritic cells pulsed with OVA peptide (SIINFEKL) (American peptide) or dendritic cells 
alone at ratio of 1:40 in the presence of BD™ GolgiStop™ (according to the manufacturer’s 
instruction, BD Pharmingen™). After 4 h, cells were fixed and permeabilized using BD 
Cytofix/Cytoperm™ kits (according to the manufacturer’s instruction, BD Pharmingen™), 
and subsequently stained with anti-mouse IFN-γ (clone XMG1.2, BD Pharmingen™) and 
anti-mouse TNF-α (clone MP6-XT22, BD Pharmingen™).
Cytokine multiplex assays
Murine OT-1 BTLA KO cells overexpressing BTLA WT or mutants were re-stimulated with 
either 10 ng/ml anti-mouse CD3 (Clone 145-2C11, BD Pharmingen™) alone or with 
recombinant mouse HVEM-Fc (R&D systems) plate-bound for 24 h. Supernatants were 
collected to quantify the secreted cytokines using a MILLIPLEX MAP Mouse CD8+ T Cell 
Magnetic Bead Panel (Millipore).
Killing assays
T cells were co-cultured with tumor cells labeled with eFluor670® at ratio of 1:1, 1:3, and 
1:10. After 3 h, the cells were fixed and permeabilized using BD Cytofix/Cytoperm 
(according to manufacturer protocol, BD Pharmingen™), then stained with anti-cleaved 
caspase-3 (clone CPP32, BD Pharmingen™), and analyzed by a BD FACSCanto II (BD 
Biosciences).
Cell proliferation assay
Murine OT-1 BTLA KO expressing BTLA WT or mutants were labeled with eFluor670® 
and re-stimulated with dendritic cells alone or dendritic cells pulsed with OVA peptide 
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(SIINFEKL) (American peptide) at a ratio of 1:40 for 48 h prior to being analyzed using a 
BD FACSCanto II (BD Biosciences).
Nanowell array-based cytolytic assay
TIL and Tumor cells were labeled with 1 µmol/L of red fluorescence dye (PKH26, Sigma) 
and 1 µl of green fluorescence dye (PKH68, Sigma) respectively. The cells were loaded onto 
nanowell at concentration of 1×106/mL. Target cell cytolysis mediated by TIL was 
monitored using a Carl Zeiss Axio Observer fitted with Hamamatsu EM-CCD camera using 
10 × 0.3 NA objective. Apoptotic cells became green when stained with Annexin V 
conjugated with Alexa 647as previously described (22).
In vivo killing of melanoma tumors using an NSG ACT model
NOD-scid IL2Rgammanull (NSG) mice were engrafted with either 5 × 106 MEL 526 MEL 
tumor cells or 5 × 106 autologous primary melanoma tumor cells. On day 12, either 10 ×106 
sorted CD8+BTLA+ or sorted CD8+BTLA− were adoptively transferred into tumor-bearing 
mice (n= 5 to 8 per group). Recombinant human IL-2 (Proleukin, Prometheus) was 
administered intraperitoneally at a concentration of 6 ×105 I.U. immediately after TIL 
transfer and daily for three days. Tumor size was measured every other day. Mice were 
sacrificed when tumors exceeded 15 mm diameter. Peripheral blood was collected every 
other day, lysed with ACK lysis buffer, then stained for AQUA (Invitrogen), anti-human 
CD45 (clone HI30, BD Pharmingen™), and anti-human CD8 (clone RPA-T8, BD 
Pharmingen™).
Vaccination model
C57BL/6J mice were intravenously administered 0.5 × 106 naïve pmel-1 or OT-I T cells, and 
vaccinated with gp100 peptide or OVA peptide (100µg) together with anti-CD40 (50 µg) and 
imiquimod (50 mg). Recombinant human IL-2 at 1.2 ×106 IU was administered once, and 6 
× 105 IU twice daily for the next 2 days (i.p.). Peripheral blood was collected every other 
day to determine the frequency of circulating pmel or OT-I T cells. Mice were boosted with 
gp100 or OVA peptide following the contraction phase and peripheral blood was collected 
every other day. Mice were sacrificed on day 120, and splenocytes were isolated to 
determine the presence of pmel T cells.
Animals
NOD-scid IL2Rgammanull (NSG) mice were purchased from the Jackson Laboratory (Bar 
Harbor, ME). OT-1 BTLA KO C57BL/6 and Pmel BTLA KO C57BL/6 mice were kindly 
provided from Dr. Roza Nurieva. Pmel BTLA WT C57BL/6 mice were kindly provided by 
Dr. Willem Overwijk. C57BL/6 mice were purchased from Charles River Labs. All mice 
were housed in a specific pathogen-free facility at The University of Texas M.D. Anderson 
Cancer Center. Animal protocols were approved by The University of Texas M.D. Anderson 
Cancer Center (#00001229 (RN)).
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Statistical analyses
Statistical analyses were performed using GraphPad Prism and the R system. For all survival 
curve analysis data, a long rank test was used to compare distribution of the two groups. We 
applied Linear models and empirical Bayes methods to compare the differential protein 
expression from RPPA data sets. Differences in tumor cell death of B16OVA and B16F10 
and the percentage of positive virally transduced mouse T cells producing IFN-γ and TNF-α 
were analyzed using a two-way ANOVA, and a two-tailed Student’s t-test was used to 
determine statistical significance for all other analyses.
Results
High expression of CD8a and BTLA correlates with an improved survival of stage III 
metastatic melanoma patients
To investigate whether BTLA is associated with melanoma patient survival, we conducted a 
Kaplan-Meier survival analysis in stage III metastatic melanomas according to gene 
expression data in tumor tissues from TCGA (The Cancer Genome Atlas) (23). We found 
that patients expressing high transcript levels of either CD8a or BTLA had much better 
survival as compared with either CD8a low or BTLA low respectively (CD8a high vs CD8a 
low, P=0.0007, N=42; BTLA high vs BTLA low, P=0.001, N=42) (Fig. 1a and 1b). When 
both markers were analyzed together, the association of CD8a high and BTLA high 
conferred the greatest survival benefit as compared with other combinations (CD8a high 
BTLA high vs CD8a low BTLA low, P =0.0006, N =98) (Fig. 1c). BTLA can be expressed 
by immune cells other than T cells such as NK cells, B cells or dendritic cells, with the 
highest levels found in B cells (5). Interestingly, we did not observe improved survival in 
patients with high BTLA expression when associated with either high NK cells (identified 
by the expression of NCR1) or B cells (CD19) (Supplementary Fig. S1a and S1b). This data 
suggests that high BTLA expression in association with high CD8+ signal is associated with 
improved melanoma patient survival. The co-expression of CD8 and BTLA cannot be 
inferred by gene expression profiling from tumor tissue however the improved survival 
benefit measured in conjunction with BTLA and CD8 expression is not seen when BTLA is 
evaluated in conjunction with markers from other cell populations known to express BTLA. 
This data lends support to our hypothesis that CD8+BTLA+ TIL exert efficient anti-tumor 
control based on our previous observation that this T cell population correlated with better 
response to TIL ACT (4).
CD8+BTLA+TIL subset exhibits greater in vivo tumor control
It has been noted that more differentiated T cells secrete more cytotoxic and cytolytic 
proteins compared to less-differentiated T cells (24). Thus, we conducted both in vitro and in 
vivo tumor control studies to compare the killing capacity of the BTLA+ and BTLA− CD8+ 
TIL subsets. To determine CTL-mediated tumor killing and ensure an equal tumor-specific 
population of both BTLA subsets, MEL 526 melanoma tumor cells expressing the MART-1 
antigen were co-cultured with either sorted MART-1 recognizing (tetramer positive) 
CD8+BTLA+ (CD8+MART-1+BTLA+) or CD8+BTLA− (CD8+MART-1+BTLA−). We 
found comparable MART-1 antigen-specific tumor killing ability after a short term (3h) TIL 
and tumor co-incubation between the BTLA+TIL and BTLA−TIL subsets in two TIL lines 
Ritthipichai et al. Page 7
Clin Cancer Res. Author manuscript; available in PMC 2018 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(Fig. 2a left panel TIL#2559 and mid panel TIL #2765). In addition, comparable killing 
ability was observed using bulk non-antigen restricted, sorted BTLA subsets in a third TIL 
line (Fig. 2a, right panel TIL #2549). Since we did not observe a difference in in vitro 
killing between the two subsets, but have demonstrated a better clinical outcome in patients 
infused with more CD8+BTLA+ TIL, we next determined whether this subset could exhibit 
better in vivo tumor control. Immunodeficient NOD-scid IL2Rgammanull mice (NSG) were 
engrafted with 5×106 MEL 526 human melanoma tumor cells for 10 days prior to adoptive 
transfer of 10×106 human CD8+MART+BTLA+TIL or CD8+ MART+BTLA−TIL. Tumor 
burden was measured every other day and transferred TIL were quantified from peripheral 
blood based on the expression of CD45 and CD8. We observed that the CD8+BTLA+ TIL 
subset exhibited significantly better tumor control on day 14 as compared with its BTLA− 
counterpart in NSG mice treated with either MART-1 tumor antigen restricted TIL line 
(2559 MART+; P=0.002 (Fig. 2b, left panel and 2765 MART+; P=0.042 (Fig. 2b mid 
panel)) as well as in a non-tumor antigen restricted setting (2549; P=0.049) (Fig. 2b, right 
panel). In addition, we found that the level of the CD8+BTLA+ TIL subset in the peripheral 
blood was significantly higher than the CD8+BTLA− subset early after therapy in mice 
treated with antigen-specific TIL lines (2559 MART+; P=0.039 on day 4, (Fig. 2c, left 
panel) 2765 MART+; P=0.0021 and 0.02 on day 2 and 4 respectively (Fig. 2c, mid panel)), 
but not in those treated with the non-restricted antigen-specific TIL line (2549; P=0.06 on 
day 2) (Fig. 2c, right panel). In summary, this data suggests that the CD8+BTLA+ and 
CD8+BTLA− TIL subsets are equally able to directly kill tumor targets in a short term in 
vitro assay. However, the BTLA positive subset provides superior in vivo tumor control and 
tends to persist better following TIL transfer.
Shorter target seeking but longer target killing time for CD8+BTLA+ TIL subset
As demonstrated above, the CD8+BTLA+ subset provides significantly better tumor control 
than its CD8+BTLA− counterpart in vivo; however, this difference is not observed in an in 
vitro setting. Because our previous in vitro tumor killing experiments were conducted using 
population assays and for only 3 hours, this limited our ability to track T cell fate following 
tumor target cell interactions. To further understand the behavioral difference between the 
CD8+BTLA+ and CD8+BTLA− subsets in mediating tumor killing, we utilized Timelapse 
Imaging Microscopy In Nanowell Grids (TIMING), to study the dynamic interactions 
between individual tumor targets and effector T cells in high-throughput (25,26). To this 
end, labeled tumor cells and TIL were loaded onto the nanowell chip, consisting of 28,224 
wells regularly separated in 7×7 blocks, and the interactions were quantified at two separate 
effector-to-target cell ratios of 1:1 and 1:2. This assay allowed us to dissect the kinetics of T 
cell killing by calculating the following sequential parameters: 1) Time needed to establish 
conjugation between the T cell and tumor target (tseek), 2) duration of the contact between 
the T cell and the tumor target (tcontact), and 3) time between the first T cell contact with the 
tumor cell and tumor cell apoptosis (tdeath) (Fig. 3a). Interestingly, the CD8+BTLA+ subset 
was more efficient in tumor seeking at effector-to-target cell ratios of 1:1 (N = 3319) as the 
time utilized to make first contact with tumor cells was significantly less than that of the 
CD8+BTLA− subset (P<0.0001) (Fig. 3b, left panel). This difference was not observed 
when 2 targets were present in the well (1:2, P=0.22) (Fig. 3b, left panel). It is possible that 
loading 2 targets in each nanowell rendered the distance to travel to meet each target too 
Ritthipichai et al. Page 8
Clin Cancer Res. Author manuscript; available in PMC 2018 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
short to be able to measure a difference in the ability of T cell subsets to seek the target. 
However, in comparison to CD8+BTLA− TIL individual CD8+BTLA+ TIL spent longer time 
in contact with a tumor cell target and induced apoptosis with slower kinetics at both E:T 
ratios studied (tcontact; 1:1 and 1:2, P<0.0001, tdeath; 1:1 and 1:2, P<0.0001) (Fig. 3b, mid 
and right panels, respectively). Overall, individual CD8+BTLA+ TIL found their target 
faster, but required longer durations to complete tumor cell killing (Supplementary Movie 1 
and 2).
CD8+BTLA+ TIL subset is characterized by a heightened ability to kill multiple targets
We next examined whether one subset was more potent in its overall tumor killing capacity 
by evaluating tumor target cell survival over the 8 hour co-culture period. Overall, both T 
cell subsets killed 18% of the tumor targets at an E:T ratio of 1:1 (Fig. 3c, red inner circle). 
However, at the 1:2 ratio the CD8+BTLA+ subset was able to kill a total of 21% of the tumor 
targets upon contact as opposed to only 14% for the CD8+BTLA− subset (Fig. 3c, red and 
green sections, outer circle). Secondly, when presented with two tumor targets, the 
CD8+BTLA+ subset was twice as likely to kill both targets (14% for the BTLA+ vs 7% for 
the BTLA, Fig. 3c).
Examination of the kinetics of tumor killing offered clues to understand the differences in 
the overall killing potential of the two subsets. The analysis of the full 500 minutes assay 
revealed a different killing pattern early after tumor encounter (first 250 minutes) in 
comparison to the second half of the incubation (last 250 minutes). A close look at the first 
250 minutes demonstrated that the CD8+BTLA− subset was more effective in tumor killing 
than the CD8+BTLA+ subset as the survival of the contacted tumor targets dropped 
significantly faster when co-incubated with CD8+BTLA− TIL at effector-to-target cell ratios 
of 1:1 and 1:2 (left panel 1:1, P<0.03, right panel 1:2, P<0.0001) (Fig. 3d). However, the 
overall percentage of killed targets at both ratios at the 250 minutes mark is the same 
between both TIL subsets. Therefore, the killing potential of the two subsets is comparable 
in the first 250 minutes but their kinetics of killing are different.
Over the last 250 minutes of the assay the picture changes (Fig. 3e). The blue curve 
(BTLA+) now dips below the red curve (BTLA−), signifying that the BTLA+ subset is 
catching up with the BTLA− subset in terms of the speed at which it kills (E:T ratio of 1:1, 
p=0.54), or takes a significant lead (E:T ratio of 1:2, p<0.0001). It is also worth noting that 
very limited killing occurs with the BTLA− in the second half of the experiment at any ratio 
while the BTLA+ subset achieves higher killing when more targets are present in the well 
(1:2). We reasoned that this situation could be explained by a differential ability for serial 
killing, or the ability to kill a second target, which can only be detected if there is more than 
one target in the well therefore at a 1:2 ratio (Fig. 3e).
Improved survival of the CD8+BTLA+ TIL subset following killing of a target
After activation, T cells can be eliminated through the process of activation-induced cell 
death (AICD). The ability of the CD8+BTLA+ subset to kill multiple targets could be linked 
to an enhanced ability to survive AICD after completing its effector function. To test this 
hypothesis, we quantified effector T cell death after a tumor killing event. We found that in 
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fact, CD8+BTLA− are more susceptible to undergo apoptosis as compared with their 
CD8+BTLA+ counterpart (P<0.01) (Fig. 3f). This data demonstrates that the CD8+BTLA+ 
subset survives better after killing a tumor target and thus is able to sustain its cytotoxic 
functionality and eliminate additional tumor cells. In summary, these results argue that both 
subsets kill equally well in a short-term killing assay (250 minutes) but the differences 
emerge when the T cell and tumor co-incubation is prolonged to 8 hours wherein the 
CD8+BTLA+ TIL subset is found to have an increased propensity to survive a killing event 
and therefore function as serial killers, thus confirming that the CD8+BTLA+ TIL subset is 
qualitatively better consistent with the in vivo results (Supplementary Movie 3).
Memory recall response is defective in BTLA deficient T cells
Our data suggests a difference in survival of BTLA+ anti-tumor CD8+ T cells rather than a 
change in killing potential. We next sought to evaluate the long-term fate of CD8+BTLA+ 
antigen-specific T cells after in vivo antigenic challenge in an immunocompetent animal. 
Our study of the expression of BTLA in human and mouse CD8+ T cells showed a different 
expression pattern (Supplementary Fig. 2 and 3). Murine naïve CD8 (CD44lowCD62Lhigh) 
are negative for BTLA but expression of BTLA is acquired as the cells differentiate to 
memory (CD44high) while human naïve CD8 (CCR7+, CD45RA+) are positive for BTLA 
and expression is progressively lost as the CD8 differentiate to terminal effector cells 
(EMRA, CCR7−, CD45RA+). However memory stages of differentiation are positive for 
BTLA in both mouse and human. Based on this we reasoned that a vaccination model would 
be the most appropriate in vivo antigen trigger to measure the role of BTLA on the function 
of CD8. We aimed to measure the impact of BTLA expression on newly generated memory 
CD8+ T cells on their capacity to respond to a second antigen exposure (recall). In this study, 
we sought to determine the role of BTLA in the persistence of antigen-specific CD8+ T cells 
in vivo after antigenic stimulation. We used TCR transgenic CD8+ T cells that are either WT 
or KO for BTLA and study their response to immunization and memory-recall response 
using a mouse vaccination model as previously described (27). Splenocytes (5e5) from either 
Pmel-1 WT or Pmel-1 BTLA KO (recognizing gp100 peptide) were adoptively transferred 
into C57BL/6 recipient mice. On the following day, mice were vaccinated with gp100 
peptide together with anti-mouse CD40. Imiquimod cream 5% was also applied on the 
vaccination site to boost the innate immune response. Additionally, IL-2 was also provided 
to support in vivo T cell proliferation following vaccination (Fig. 4a and b). The frequency 
of Pmel-1 T cells was tracked in peripheral blood after vaccination (Fig. 4c). On day 20 
following priming, we observed a significantly higher frequency of Pmel-1 WT in peripheral 
blood when compared with Pmel-1 BTLA KO. The frequency of both Pmel-1 WT and 
Pmel-1 BTLA KO contracted to pre-priming frequency by day 30. Boost vaccination was 
performed on day 60. We observed that Pmel-1 WT T cells had a robust recall response that 
was absent in the Pmel-1 BTLA KO group (Fig. 4c). To determine the impact on the 
generation of a long-term memory response, we assessed the frequency of Pmel-1 T cells in 
the spleen on day 120. We found a significantly higher percentage of Pmel-1 WT T cells in 
the spleen as compared to Pmel-1 BTLA KO T cells (Fig. 4d, p=0.038). Similar data was 
obtained with the transfer of BTLA WT or KO OT-1 T cells and vaccination with OVA 
peptide SIINFEKL (Supplementary Fig S4). In this context, the use of BTLA KO OT-1 T 
cells led to a marked attenuation of the recall response but not the complete lack observed 
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with the Pmel-1 T cells. Nonetheless these results suggests that BTLA is critical for the 
generation of a recall memory response.
Dichotomous BTLA signaling: ITIM/ITSM dampens effector cytokine secretion while Grb2 
enhances IL-2 production
Our in vivo experiments with human TIL and single cell killing analyses have suggested that 
the CD8+BTLA+ subset is endowed with a superior pro-survival function leading to better 
anti-tumor activity. Conceivably, the superiority of this subset could result from either 1) 
properties of less-differentiated T cells marked by BTLA expression or 2) signaling through 
the BTLA molecule itself. Our vaccination study suggests a direct involvement of the BTLA 
molecule. However, to further test the contribution of the BTLA signaling, we performed 
functional studies of BTLA by overexpressing wild-type BTLA (WT BTLA) or variants of 
BTLA’s intracellular motifs in OT-1 T cells from OT-1 BTLA KO mice. To dissect the 
signaling contributions from the ITIM/ITSM and the Grb2 motifs independently, retroviral 
constructs were generated with point mutations by substitution of tyrosine for phenylalanine 
in either the Grb2 binding motif (ΔGrb2) or the ITIM and ITSM motifs (ΔITSM) (Fig. 5a). 
OT-1 BTLA KO T cells were transduced with constructs containing WT BTLA, ΔGrb2, and 
ΔITSM as well as an empty vector control (EM). Virally transduced OT-1 T cells were co-
cultured with either B16F10 (negative for OVA antigen) or B16OVA tumor cells at an 
effector to target ratio of 1:10, 1:3, and 1:1. HVEM expression on both tumor targets was 
confirmed by flow cytometry (Supplementary Fig. S5). Indeed, the tumor killing capacity of 
the TIL in this short term in vitro assay was comparable regardless of the presence of WT 
BTLA or BTLA mutants at all ratios tested (ratio 1:1, P=0.67; ratio 1:3, P=0.46; ratio 1:10, 
P=0.29) (Fig. 5b). We did not observe differences in the number of T cells producing IFN-γ 
or TNF-α among these different groups (IFN-γ, P=0.11; TNF-α, P=0.59) (Fig. 5c, left 
panel). However, the amount of effector cytokines being made by the WT BTLA transduced 
T cells was significantly less than that made by those transduced with the empty vector alone 
following re-stimulation with dendritic cells pulsed with OVA peptide (IFN-γ MFI; EM vs 
WT, P=0.04, TNF-α MFI; EM vs WT, P=0.0045) (Fig. 5c, right panel). The BTLA-
mediated inhibition of IFN-γ and TNF-α production was relieved by the disruption of the 
ITIM/ITSM motifs; however, it was not significantly impacted by the disruption of the Grb2 
motif, suggesting that ITIM and ITSM motifs are mainly involved in regulating the amount 
of effector cytokines produced following TCR triggering.
We have previously demonstrated that the CD8+BTLA+TIL subset had an improved 
proliferative capacity in response to IL-2 (14). Thus, we sought to determine whether BTLA 
signaling motifs could play a role in T cell proliferation. OT-1 BTLA KO T cells 
overexpressing BTLA WT or mutants were labeled with the cell proliferation dye 
eFluor670® and re-stimulated with dendritic cells pulsed with OVA peptide for two days. T 
cell proliferation was comparable between control and WT BTLA groups. (MFI: WT versus 
EM; P=0.30) (Fig. 5d, histogram). On the other hand, subtle differences are appreciable 
between T cells expressing the different BTLA constructs. We observed that OT-1 BTLA 
KO T cells expressing ΔITSM had a lower mean fluorescence intensity (MFI) of the 
eFluor670® dye as compared with the empty vector control which is indicative of a more 
robust proliferation (MFI: ΔITSM versus EM; P=0.012, ΔITSM versus WT; P=0.0057) (Fig. 
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5d). On the contrary, attenuation of T cell proliferation was observed in T cells expressing a 
disrupted Grb2 motif (ΔGrb2), (MFI: ΔGrb2 versus ΔITSM; P=0.0003, ΔGrb2 versus EM; 
P=0.0008, ΔGrb2 versus WT; P= 0.0009) (Fig. 5d). These data suggest that the T cell 
proliferation post TCR triggering is regulated positively by the Grb2 motif and negatively by 
ITIM/ITSM motifs.
Our previous report demonstrated that CD8+BTLA+ human TIL produce more IL-2 upon 
activation (14). Thus, we further investigated whether BTLA signaling could be responsible 
for IL-2 secretion. OT-1 BTLA KO T cells overexpressing WT BTLA or its mutants were 
re-stimulated with anti-CD3 in the presence of HVEM-Fc fusion protein to engage the 
BTLA molecule, and IL-2 secretion was assessed. Indeed, we found that IL-2 production 
was significantly increased in activated T cells transduced with the BTLA WT and ΔITSM 
constructs, but not in ΔGrb2 and the empty vector. This suggests that the BTLA-dependent 
IL-2 production was mediated through Grb2 motif, independently of the ITIM/ITSM motifs 
(WT versus EM; P=0.02, ΔITSM versus EM; P=0.005, WT versus ΔGrb2; P=0.02, ΔITSM 
versus ΔGrb2; P=0.01, EM versus Grb2; P=0.79, WT versus ΔITSM; P=0.32) (Fig. 5e). This 
data highlights that Grb2 signaling contributes to IL-2 production following BTLA ligation 
during T cell activation. A summary of the phenotypes seen with the expression of BTLA or 
its variants is presented in Fig. 5a (right panel).
Signaling downstream of mouse BTLA
To identify proteins activated downstream of BTLA, we employed Reverse Phase Protein 
Array (RPPA), a high-throughput method developed for functional proteomic studies. OT-1 
BTLA KO mouse T cells overexpressing WT BTLA or BTLA mutants were stimulated with 
anti-CD3 with or without HVEM-FC for 8 hours. The full list of tested proteins can be 
found in Supplementary Table S3. The protein expression levels found in activated T cells 
transduced with BTLA WT was used as a reference to compare the differential protein 
changes in ΔGrb2 and ΔITSM. The protein expression profile of the T cells expressing the 
BTLA variants were also compared to that obtained with the empty vector. (Supplementary 
Table S4). We observed that the phosphorylation of Akt at T308 as well as the 
phosphorylation of one of its substrates, pPRAS40 at T246, were significantly attenuated in 
ΔGrb2 in comparison to BTLA WT (pAkt T308; P=0.045, pPRAS40 T246; P=0.007) (Fig. 
6a, left panel and Supplementary Table S4) (28). As expected, the disruption of ITIM/ITSM 
motif resulted in a remarkable enhancement of the phosphorylation of several proteins such 
as Src, Chk1, Chk2, as well as members of the Wnt pathway GSK-3b, and of Beta-Catenin 
at T41 and S45 (pSrc at S527; P=0.005, pA-Raf at S299; P=0.01, and pC-Raf at S338; 
P=0.02, pChk1 at S286; P=0.01, pChk2 at T68; P=0.02, GSK-3b at S9; P=0.04, Beta-
Catenin at T41 and S45; P=0.04) (Fig. 6a, right panel and Supplementary Table S4).
BTLA-HVEM axis in human TIL selectively suppresses Akt and NF-kB pathways but 
enhances Src pathway
To exclude the bias of overexpression of WT BTLA and genetically modified BTLA in 
BTLA knockout mouse, we further investigated BTLA signaling pathway in human TIL, 
which is more physiologically and clinically relevant to our observation in our adoptive T 
cell therapy clinical trial. Sorted CD8+BTLA+ human TIL were stimulated with plate bound 
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anti-human CD3 at concentrations of 10, 30, 100, 300, and 1000 ng/mL with or without 
HVEM-Fc for 8h and proteins extracted from cell lysates were used to perform RPPA in 5 
separate patient TIL samples. We observed a general decrease in differentially 
phosphorylated protein changes in several signaling pathways when T cell activation 
happened in the presence of HVEM. These included the MAPK kinase pathway (pP38 at 
T180; P=2.08 × 10−9, pP90RSK at T573; P=3.26 × 10−4, pS6 at S235; P= 1.68×10−2), NF-
κB pathway (pNF-κB p65 at S536; P=3.15 × 10−2), the Akt pathway (pAKT at S473; 
P=9.6×10−3), and the Beta-catenin pathway (GSK-3a–b pS21; P=9.6×10−3) (Fig. 6b and c 
and Supplementary Table S5). Inhibition of these positive signaling pathways clearly support 
the role of BTLA as a co-inhibitory molecule. Interestingly, we found a significant elevation 
of Src phosphorylation at S416 (pSrc at S416; P= 3.36 × 10−6) when the T cell activation 
happened in the presence of HVEM. Our results suggest that the TCR signaling pathway is 
not completely suppressed by BTLA, but is specifically attenuated in certain pathways as 
indicated above and specifically potentiated in very select pathway(s). Unexpectedly, we 
found that phosphorylation of HER2 at tyrosine 1248 was prominently increased in an anti-
CD3 dose-dependent manner regardless of the presence of HVEM. This strengthens the 
notion that the BTLA/HVEM axis acts on specific targets. To further comprehensively 
understand the downstream signaling pathway of human BTLA, we generated the signaling 
network of proteins significantly changed during HVEM ligation using Ingenuity pathway 
analysis (IPA). We observed that Src signaling node was exclusively clustered and separated 
from Akt, NF-kB, and Beta-catenin signaling nodes. This suggests that the Src signaling 
pathway is likely not or minimally interfered by SHP1/2 (Fig. 6d).
Discussion
Our recent report demonstrated that the CD8+BTLA+ TIL are less differentiated, respond 
better to IL-2 and persist longer in the patient post infusion (14). In the current study, we 
shed light on the dichotomy of the signaling downstream of BTLA and highlight a role for 
BTLA in the development of CD8+ T cell memory-recall and the survival of effector 
memory CD8+ T cells sustaining their anti-tumor function.
We observed that the CD8+ BTLA+ and CD8+ BTLA− subsets had comparable in vitro 
killing, which did not explain the superiority of the CD8+ BTLA+ subset in controlling 
disease in patients. The use of a single cell nanowell-based cytolytic assay helped elucidate 
fundamental differences between the two subsets. Importantly, the results demonstrated that 
both subsets efficiently kill a first target but the CD8+BTLA+ subset is more likely to survive 
after this killing event and kill another target, thus providing a rationale for the improved in 
vivo efficacy of the CD8+BTLA+ TIL.
The defective recall response seen in BTLA KO antigen-specific T cell in vivo models used 
contrasts with previous literature. A publication by Krieg et al evaluates the response of the 
CD8+ BTLA-KO OT-1 T cells in a vaccination model and claims that there is more efficient 
memory formation in the BTLA-KO OT-1 T cells than their WT counterpart (29). This claim 
is based on the fact that there are twice as many CD8+ OT-1 BTLA-KO T cells than WT 
counterpart in the spleen 30 days after the primary stimulation even though the BTLA-KO 
OT-1 subset peaked at lower frequency in the early days of the primary response. The 
Ritthipichai et al. Page 13
Clin Cancer Res. Author manuscript; available in PMC 2018 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
BTLA-KO OT-1 also had a slightly lower fold expansion early (day 4) during the secondary 
expansion (7 fold versus 10 fold) following boosting with peptide-pulsed DC. This is in 
contrast with the data obtained when boosting with an infectious agent expressing OVA, 
LM-OVA, where the BTLA-KO OT-1 expand more than the BTLA WT OT-1 at day 5 (91 
fold versus 191 fold). Unfortunately the experiment was not carried out longer. The authors 
conclude that BTLA KO OT-1 can form memory, and that the amplitude of the recall 
response may depend on the type of antigenic challenge used. Interestingly, another study 
utilizing BTLA KO animals and LM-OVA infection concluded that HVEM expression on T 
cells transduces a survival signal through interaction with BTLA expressed on other cells in 
the host and that interaction was required for CD8+ T cell memory generation(30).
There are a few key differences between our vaccination model and the reported studies. 
First of all, the adoptive cell transfer in the paper by Krieg et al is performed to allow 
competition between the cell subsets in the host. The authors actually transfer both BTLA 
WT OT-1 and BTLA KO OT-1 T-cells at a 1:1 ratio to BTLA WT hosts and vaccinate the 
animals one day later with peptide-pulsed dendritic cells. While these experiments were 
designed to test BTLA’s function, the known expression of BTLA’s receptor, HVEM, on 
activated T cells, and its ability to transduce a survival signal by interactions in trans may 
become a confounding factor. In this system it is possible that BTLA expressed on BTLA 
WT OT-1 may have interacted with HVEM on both transferred subsets which could have 
delivered a survival signal potent enough to limit the contraction phase and enhance memory 
formation for both subsets. The amplitude of the memory generation in this system could be 
controlled by the strength of TCR signal which clearly will be stronger in BTLA KO OT-1 
since all studies are in agreement that BTLA suppresses TCR signaling.
Our experiments were designed to study the response of the two subsets separately, in 
different animals. Our data rather shows BTLA-mediated survival of T cells following 
effector function, probably due to dampening of TCR signaling and prevention of AICD. We 
believe that BTLA acts as a rheostat reducing TCR signaling during strong or chronic 
antigenic stimulation while also promoting cell survival due to the presence of both 
activating and inhibitory signaling motifs in its intracellular signaling domain. Our 
vaccination was administered by injection of the cognate peptide and anti-CD40 in saline 
subcutaneously, with topical application of the TLR 7 agonist imiquimod on the injection 
site and IP IL-2. This vaccination strategy, optimized by our collaborator Drs. Hailemichael 
and Overwijk, results in a powerful activation of the antigen-specific T-cell response (27). 
This stimulation produces a robust recall response in WT OT-1 and Pmel T cells however in 
our hands the BTLA KO OT-1 cells have a reduced ability to generate a recall response and 
Pmel BTLA KO cannot recall at all. We reasoned that BTLA expression may be essential to 
suppress overstimulation conducive to AICD and allow the survival of cells to form a 
memory pool. The method employed to vaccinate in the study by Krieg et al, the use of 
peptide-pulsed DC, may also not cause as much AICD as the stimulation used in our system, 
thus not requiring dampening of TCR stimulation by BTLA for survival.
We have demonstrated previously that resting CD8+BTLA+TIL manifested enhanced 
mitochondrial function and spare respiratory capacity (SRC) as compared to their 
CD8+BTLA− TIL counterpart (31). High SRC has been reported to be a feature of memory 
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CD8+ T cells distinguishing them from naïve and effector subsets, and was found to play a 
role in survival of the memory CD8+ subset conducive to the establishment of a long-lived 
memory pool (32). Our findings of the better survival of the CD8+BTLA+ TIL subset after a 
killing event are consistent with a pro-survival advantage. A recent study indicated that 
increased SRC was strongly associated with a superior bioenergetic capacity, which helped 
improve T cell survival and motility under hypoxic conditions (33). The intrinsic properties 
of this subset provide an intriguing possibility for why infusion of large numbers of 
CD8+BTLA+TIL positively correlates with clinical response to TIL ACT in metastatic 
melanoma patients.
We have found that a BTLA-dependent potentiation of IL-2 secretion entirely depends on 
Grb2 motif. Disruption of the ITIM and ITSM motifs did not alter the levels of IL-2 induced 
by BTLA, suggesting a signaling pathway independent of the pro-inhibitory influence of 
ITIM and ITSM. Our findings are consistent with previous reports that have shown that 
Grb2-linked SLP-76 and Vav interaction are involved in IL-2 production, and that 
recruitment of Grb2 is essential for CD28-induced IL-2 production (34–36). Our current 
study reveals that BTLA engagement in the context of TCR stimulation results in IL-2 
production in a manner similar to CD28 which positions BTLA as both a co-inhibitory and 
co-stimulatory molecule. The in vivo relevance of BTLA-dependent IL-2 production in the 
context of T cell activation warrants further study. Autocrine IL-2 production by CD8+ T 
cells has been shown to be essential for secondary expansion of CD8+ memory T cells 
which could potentially explain the lack of secondary expansion seen in BTLA KO cells 
after boosting with the vaccinating antigen (37). The pro-survival properties conferred by 
BTLA on CD8+ T cells may come from the interaction of BTLA with HVEM on activated T 
cells as it was demonstrated for CD4+ murine T cells (38,39) However the HVEM 
interaction with its alternative ligand LIGHT rather than BTLA has been implicated in 
furthering CD4+ T cell activation and survival(39). In our experiments, the absence of BTLA 
may render HVEM available to bind to its alternative ligand LIGHT to provide co-
stimulatory signaling to T cells however this mechanism was not sufficient to rescue the 
establishment of memory cells able to respond to a recall antigen stimulation.
Conversely we did not observe any major differences in in vitro killing capacity and 
cytotoxic cytokine production between BTLA KO T cells versus BTLA KO T cells 
overexpressing BTLA WT or its mutants. This suggests that BTLA signaling does not affect 
tumor killing capability. Our findings are consistent with the previous report showing that 
the BTLA blockade in γδT cells had no effect on the tumor lysis (40).
We did not observe a significant impact of WT BTLA when the molecule was reintroduced 
in BTLA KO T cells. However, malfunction of ITIM and ITSM motifs significantly 
enhanced T cell proliferation while Grb2 alteration reduced the proliferation. A lack of 
impact of BTLA on CD4+ T cell proliferative response has been reported previously (12). 
Previous studies in both human and mouse settings indicated that CD8+ T cells were 
intrinsically less susceptible to BTLA-mediated inhibition as compared to CD4+ T cells 
(9,41). This might explain the minimal inhibition of WT as compared to EM in CD8+ T cells 
in terms of proliferation.
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We noticed that the Akt signaling pathway was remarkably attenuated in BTLA ΔGrb2, 
while the phosphorylation of Src was enhanced in BTLA ΔITSM. This finding is consistent 
with a previous report demonstrating that ITIM and ITSM motifs of PD-1 inhibited signals 
through Akt and MAPK (10). However, in the presence of co-stimulation mediated through 
the BTLA Grb2 motif, as in the case of ΔITIM/ITSM, the phosphorylation of Akt was 
unaltered, suggesting that Grb2 is not directly involved in maintaining or augmenting Akt 
phosphorylation. Taken together, this data suggests that the Akt pathway in BTLA was likely 
targeted by SHP1/2, similar to what was found in PD-1.
Overexpression of Grb2 in osteoclasts was shown to promote phosphorylation of Src at 
Y416 and the opposite result was obtained when Grb2 expression was disrupted (42). From 
our data, it is clear that the phosphorylation of Src increased when Grb2 was providing 
BTLA signaling in the absence of functional ITIM and ITSM motifs. This could result from 
either the direct effect of Grb2 signal transduction or the lack of dephosphorylation normally 
caused by SHP1/2 via ITIM and ITSM motifs. Since the phosphorylation of Src is not 
significantly influenced by the ITIM/ITSM co-signaling (ΔGrb2), we conclude that it is 
likely to be Grb2 mediated Src activation.
Our data of BTLA signaling in mouse T cells was found to be consistent with changes 
observed when activated human CD8+BTLA+TIL were co-stimulated by HVEM. Indeed, 
we observed an attenuation of MAPK, NF-κB, and Akt signaling proteins, but 
phosphorylation of Src was enhanced when human TIL were stimulated with anti-CD3 and 
HVEM as compared to CD3 alone. This suggested that the downstream signaling pathway 
of BTLA in mice and humans possibly share similar downstream signaling targets.
Overall, our study sheds light on a dual role of BTLA as both a co-stimulatory and co-
inhibitory molecule. This observation is supported by a study reporting that the gene 
expression profile of CD4+ T cells activated with CD3 and BTLA engagement mimics the 
profile induced by co-stimulatory molecules (12). In our hands, the integration of the 
positive and negative signals transduced by BTLA promotes IL-2 secretion while reducing 
effector cytokine production and proliferation in certain contexts. In addition, the inherent 
properties of the less-differentiated T cells expressing BTLA also display enhanced 
resistance to apoptosis and an efficient bioenergetic profile providing a survival advantage 
following tumor killing. These findings support the concept that the intrinsic attribute of the 
less-differentiated CD8+BTLA+ human TIL subset together with balanced signals 
transduced by the engagement of HVEM in the tumor microenvironment on melanoma cells 
could provide a costimulatory signal to CD8+BTLA+ TIL promoting IL-2 secretion, T cell 
survival and anti-tumor function.
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Translational Relevance
BTLA (B-and-T lymphocyte attenuator) is a negative T cell co-signaling molecule. Its 
expression on CD8+ Tumor-Infiltrating Lymphocytes (TIL) unexpectedly associated with 
better clinical outcome in metastatic melanoma patients treated with adoptive T-cell 
therapy using TIL. We sought to determine whether BTLA signaling could positively 
impact T cells. Our results demonstrate that the CD8+BTLA+ TIL subset has a survival 
advantage following the killing of a tumor target in comparison to its BTLA− counterpart, 
which may explain the superior in vivo persistence of this subset after TIL infusion. 
Interestingly, the Grb2 motif of BTLA was found to promote IL-2 production following 
BTLA engagement in the context of a TCR stimulation, and the presence of BTLA on 
CD8+ T cells was required to develop a robust recall response. Therefore, developing a 
strategy to selectively expand and infuse CD8+BTLA+ TIL may enhance TIL persistence 
post-infusion and result in superior clinical outcome.
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Figure 1. Correlation of BTLA and CD8a co-expression with overall survival in stage III 
melanoma
Kaplan-Meier survival curves in stage III metastatic melanoma from The Cancer Genome 
Atlas (TCGA) consortium depicts; (a) CD8a expression; CD8a high versus CD8a low (b) 
BTLA expression; BTLA high versus BTLA low (c) Combined CD8 and BTLA expression; 
CD8a high BTLA high versus CD8a low BTLA high versus CD8a high BTLA low versus 
CD8a low BTLA low. Total number of patients=98, (high- above median, low-below 
median). Statistical significance was determined using a log-rank. (P <0.001 and P <0.0001).
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Figure 2. CD8+BTLA+ TIL demonstrate a superior anti-tumor effect in vivo
(a) MART1-reactive CD8+ TIL (left and mid panel) and TIL 2549 (right panel) were sorted 
into BTLA+ and BTLA− subsets. MEL 526 (melanoma tumor expressing MART-1 antigen, 
left and mid graph) or autologous tumor line 2549 (right graph) were stained with 
eFluor670® and co-cultured with TIL at the following TIL-to-tumor cell ratios (1:10, 1:3, 
and 1:1). Tumor cell death is measured by the percentage of caspase-3 positive cells. (b) Ten 
million sorted CD8+BTLA+ or sorted CD8+BTLA− TIL were intravenously injected into 
tumor bearing mice previously subcutaneously implanted with either MEL 526 or 
autologous melanoma tumor line 2549. Tumor burden was measured using calipers and 
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diameter graphed as mm2. (c) Bar graph shows the percentage of CD45+CD8+ in the 
peripheral blood on days 2, 4, 6, and 8 post-adoptive transfer in the same experiment 
described in (b). N= 5–8 animals per group. *P <0.05, **P <0.001, ***P <0.0001. All 
values in figure are expressed as mean ± s.e.m. P-values were calculated using a two-tailed 
Student’s t-test.
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Figure 3. CD8+BTLA+TIL subset mediates killing of multiple tumor targets through enhanced 
survival properties
Nanowell array-based cytolysis assay was used to determine tumor killing capacity at single 
cell level. Effector cell and Tumor target are labeled in different colors and loaded into the 
nanowell at effector-to-target cell ratios of 1:1 and 1:2. Interaction between effector and 
target cells is monitored by automated time-lapse camera coupled with a fluorescence 
microscope. (a) Schematic diagram demonstrates the sequential events that effector cells 
seek (tseek), contact (tcontact), and mediate tumor cell death (tdeath). (b) Either 
CD8+MART+BTLA+ or CD8+MART+BTLA− subset was co-incubated with MEL 526. 
Time (min) between each sequential event is evaluated. Dot plots depict tseek (left), tcontact 
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(middle), tdeath (right) in comparison between CD8+BTLA+ (blue) and CD8+BTLA− (red) 
subsets. All error bars depicts the mean ± s.e.m. All P-values were calculated using a two-
tailed Student’s t-test. (N=497). (c) Donut charts demonstrate the frequency of tumor cell 
death following effector cell killing by either CD8+BTLA+ (left) or CD8+BTLA− (right) 
subset. Inner circle and outer circle depict E:T ratio of 1:1 and 1:2 respectively. (d) Kaplan-
Meier survival curves of T cell-contacted tumor target resulting in a killing event in the first 
250 minutes in comparison between CD8+BTLA+ and CD8+BTLA− subsets at effector-to-
target cells ratios of 1:1 (left) and 1:2 (right). (e) Kaplan-Meier survival curves of T cell-
contacted tumor target resulting in a killing event in the last 250 minutes minutes in 
comparison between CD8+BTLA+ and CD8+BTLA− subset at effector-to-target cells ratios 
of 1:1 (left) and 1:2 (right). Statistical significance in (d) and (e) was determined using a 
log-rank. (N=3319). (***P <0.0001). (f) Kaplan-Meier survival curves of tumor-contacted 
effector cells following tumor cell death in comparison between CD8+BTLA+ and 
CD8+BTLA− subsets at an effector-to-target ratio of 1:1. Statistical significance was 
determined using a log-rank. (N= 3319) (*P<0.05).
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Figure 4. Defective memory recall response of BTLA deficient T cells
Schematic diagram depicting experimental design of mouse model for vaccination. 0.5 × 106 
(a) Pmel-1 Thy 1.1. wild type splenocytes or (b) Pmel-1 BTLA KO splenocytes were 
adoptively transferred into C57BL/6 mouse recipients (i.v.) (n=5 mice per group). On the 
following day, the recipients were vaccinated with gp100 peptide (100µg) together with anti-
CD40 (50 µg) and imiquimod (50 mg). Recombinant human IL-2 at 1.2 ×106 IU was 
administered once, and 6 × 105 IU twice daily for the next 2 days (i.p.). Peripheral blood 
was collected every other day to determine the frequency of circulating Pmel-1 Thy 1.1 T 
cells. On day 60, the mic e were vaccinated with gp100 peptide, and peripheral blood was 
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collected every other day until Pmel-1 T cells were no longer detected. On day 120, the mice 
were euthanized, and spleens were collected to determine the presence of Pmel-1 Thy 1.1 T 
cells. (c) Plot graph depicts the percentage of CD3+CD8+Pmel+ T cells in the peripheral 
blood following the priming (first peak from day 15 to day 30) and boosting (second peak 
from day 60 to 70). The frequency of CD3+CD8+Pmel+T cells was significantly higher in 
C57BL/6 mouse recipients receiving Pmel-1 Thy 1.1 wild type splenocytes as compared to 
those receiving Pmel-1 Thy 1.1 BTLA KO splenocytes. (d) Comparison of the percentage of 
CD3+CD8+Pmel+ T cell in spleen on day 120 of mice receiving either Pmel-1 Thy 1.1 wild 
type splenocytes or Pmel-1 Thy 1.1 BTLA KO splenocytes. Pmel-1 Thy 1.1 BTLA KO 
splenocytes failed to develop memory recall response following vaccination and boosting.
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Figure 5. BTLA signaling motifs show no effect on tumor killing, while Grb2 motif augments 
IL-2 production and T cell proliferation
(a) Schematic diagram depicts the structure of BTLA WT (left), BTLAΔGrb2 (middle), and 
BTLAΔITSM (right). Signaling motifs with modified Tyrosine to Phenylalanine are 
indicated by a dotted pattern over a black background. A table summarizing the phenotype 
observed with the expression of BTLA or of the different BTLA constructs is presented on 
the right panel. (b) B16 OVA (mouse melanoma tumor positive for OVA) or B16F10 (mouse 
melanoma tumor negative for OVA) were stained with eFluor670® and co-cultured with 
OT-1 BTLA KO T cells overexpressing WT BTLA or BTLA mutants at the following T 
cell-to-tumor cell ratios (1:10, 1:3, and 1:1). Tumor cell death is depicted by the percentage 
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of caspase-3 positive cells. N=3 independent experiments (c) OT-1 BTLA KO T cells 
overexpressing WT BTLA or its variants were re-stimulated with dendritic cells pulsed with 
OVA peptide. TNF-α and IFN-γ production by virally transduced OT-1 BTLA KO T cells 
was evaluated by intracellular staining. Bar graph depicts the percentage of positive cells 
(left panel) and mean fluorescence intensity (MFI) (right panel). Each bar represents three 
independent experiments. (Two-way ANOVA; *P<0.05). (d) OT-1 BTLA KO T cells 
overexpressing WT BTLA or its variants were labeled with eFluor670® and re-stimulated 
with dendritic cells pulsed with OVA peptide. Cell proliferation was determined by the 
dilution of eFluor670®. Histogram plots of eFluor670® demonstrate proliferation of OT-1 
BTLA KO T cells overexpressing WT BTLA or its variants. Bar graph depicts MFI of 
virally transduced T cells in the same experiment shown in the left panel. N=3 *P <0.05, 
**P <0.001, ***P<0.0001. All error bars depicts the mean ± s.e.m. All P-values were 
calculated using a two-tailed Student’s t-test. (e) Virally transduced OT-1 BTLA KO T cells 
were stimulated with plate-bound anti-mouse CD3 and HVEM Fc. Supernatants were 
assessed for IL-2 production using by MILLIPLEX MAP Mouse CD8+ T Cell Magnetic 
Bead Panel Assays. Each bar graph represents two independent experiments. *P <0.05, **P 
<0.001. All error bars depicts the mean ± s.e.m. All P-value were calculated using a two-
tailed Student’s t-test.
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Figure 6. BTLA-HVEM signaling axis suppresses MAPK, Akt, and NF-κB pathways, but 
selectively augments the Src pathway
(a) OT-1 BTLA KO T cells overexpressing WT BTLA or its variants were re-stimulated 
with plate-bound anti-CD3 and HVEM-Fc for 8 h prior to harvest. Cells were lysed and the 
protein supernatant was collected to perform RPPA. Volcano plots depict fold change of 
proteins with the following comparisons: ΔGrb2 versus WT (left), ΔITSM versus WT 
(middle), and ΔITSM versus EM (right). Data shown represent two independent 
experiments. P <0.05. P-values were calculated using Linear models and empirical Bayes 
methods. (b and c) Sorted CD8+BTLA+ TIL were stimulated with plate-bound anti-CD3 (0, 
10, 30, 100, 300, and 1000 ng/ml) alone or with HVEM-Fc for 8 h prior to harvest. Cells 
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were lysed and the protein supernatant was collected to perform RPPA. (b) Volcano plot 
depicts fold change of proteins in CD8+BTLA+TIL upon T cell activation with anti-CD3 
alone (left), anti-CD3 + HVEM (middle), and anti-CD3 in comparison with anti-CD3 + 
HVEM (right). (c) Bar graph demonstrates proteins that significantly change in comparison 
between anti-CD3 activation alone (red) and anti-CD3 + HVEM ligation (blue). (d) 
Signaling network from the proteins that significantly change in (c) were clustered by 
Ingenuity Pathway Analysis. N=5, P <0.05. P-values were calculated using Linear models 
and empirical Bayes methods.
Ritthipichai et al. Page 31
Clin Cancer Res. Author manuscript; available in PMC 2018 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
